Co-Development And Commercialization Agreement Sample Contracts

Advaxis – Co-Development and Commercialization Agreement (August 5th, 2016)

This Co-Development and Commercialization Agreement (this "Agreement") is made effective as of February 3, 2016 (the "Effective Date") by and between Advaxis, Inc., a corporation formed under the laws of Delaware ("Advaxis") having its place of business at 305 College Road East, Princeton, NJ 08540, and Especificos Stendhal SA de CV, a corporation formed under the laws of Mexico City and with headquartered in Av. Camino a Santa Teresa 1040, Mezannine, Jardines en la Montana, Tlalpan, C.P. 14210 Mexico D. F. ("Stendhal"; each of Stendhal and Advaxis are a "Party", and together, the "Parties").

Palatin Technologies, Inc. – *** OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. SECTION 240.24b-2 LICENSE, CO- DEVELOPMENT AND COMMERCIALIZATION AGREEMENT Between Palatin Technologies, Inc. And Chemical Works of Gedeon Richter Plc. This Binding Agreement Was Executed on August 29th, 2014 (October 9th, 2014)
Palatin Technologies, Inc. – *** OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. SECTION 240.24b-2 LICENSE, CO- DEVELOPMENT AND COMMERCIALIZATION AGREEMENT Between Palatin Technologies, Inc. And Chemical Works of Gedeon Richter Plc. This Binding Agreement Was Executed on August 29th, 2014 (September 12th, 2014)
Acucela Inc. – Co-Development and Commercialization Agreement (January 27th, 2014)

This Co-Development and Commercialization Agreement (this Agreement) is made as of September 4, 2008 (the Effective Date), by and between Acucela Inc., a Washington corporation having its principal offices at 21720 23rd Drive SE, Suite 120, Bothell, WA 98021 (Acucela), and Otsuka Pharmaceutical Co., Ltd., a Japanese corporation (Otsuka) having its principal offices at 2-9 Kanda Tsukasa-cho Chiyoda-ku, Tokyo 101-8535, Japan. Acucela and Otsuka are each referred to herein as a Party and collectively as the Parties.

Acucela Inc. – Co-Development and Commercialization Agreement (December 17th, 2013)

This Co-Development and Commercialization Agreement (this Agreement) is made as of September 4, 2008 (the Effective Date), by and between Acucela Inc., a Washington corporation having its principal offices at 21720 23rd Drive SE, Suite 120, Bothell, WA 98021 (Acucela), and Otsuka Pharmaceutical Co., Ltd., a Japanese corporation (Otsuka) having its principal offices at 2-9 Kanda Tsukasa-cho Chiyoda-ku, Tokyo 101-8535, Japan. Acucela and Otsuka are each referred to herein as a Party and collectively as the Parties.

Acucela Inc. – Co-Development and Commercialization Agreement (July 5th, 2013)

This Co-Development and Commercialization Agreement (this Agreement) is made as of September 4, 2008 (the Effective Date), by and between Acucela Inc., a Washington corporation having its principal offices at 21720 23rd Drive SE, Suite 120, Bothell, WA 98021 (Acucela), and Otsuka Pharmaceutical Co., Ltd., a Japanese corporation (Otsuka) having its principal offices at 2-9 Kanda Tsukasa-cho Chiyoda-ku, Tokyo 101-8535, Japan. Acucela and Otsuka are each referred to herein as a Party and collectively as the Parties.

Exclusive License and Collaborative Research, Co-Development and Commercialization Agreement (March 28th, 2013)

This EXCLUSIVE LICENSE AND COLLABORATIVE RESEARCH, CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this Agreement) is made effective as of December 18, 2009, (the Effective Date), by and among ASTELLAS PHARMA INC., a Japanese corporation (API) and its indirect wholly owned subsidiary ASTELLAS US LLC, a Delaware limited liability company (AUS; collectively with API, Astellas), and AMBIT BIOSCIENCES CORPORATION, a Delaware corporation (Ambit).

Exclusive License and Collaborative Research, Co-Development and Commercialization Agreement (February 20th, 2013)

This EXCLUSIVE LICENSE AND COLLABORATIVE RESEARCH, CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this Agreement) is made effective as of December 18, 2009, (the Effective Date), by and among ASTELLAS PHARMA INC., a Japanese corporation (API) and its indirect wholly owned subsidiary ASTELLAS US LLC, a Delaware limited liability company (AUS; collectively with API, Astellas), and AMBIT BIOSCIENCES CORPORATION, a Delaware corporation (Ambit).

Exclusive License and Collaborative Research, Co-Development and Commercialization Agreement (December 20th, 2012)

This EXCLUSIVE LICENSE AND COLLABORATIVE RESEARCH, CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this Agreement) is made effective as of December 18, 2009, (the Effective Date), by and among ASTELLAS PHARMA INC., a Japanese corporation (API) and its indirect wholly owned subsidiary ASTELLAS US LLC, a Delaware limited liability company (AUS; collectively with API, Astellas), and AMBIT BIOSCIENCES CORPORATION, a Delaware corporation (Ambit).

RedHill Biopharma Ltd. – Co-Development and Commercialization Agreement (December 3rd, 2012)

THIS CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this "Agreement") is made and entered into as of August 26, 2010 (the "Effective Date"), by and between IntelGenx Corp., a Canadian corporation ("IntelGenx"), and RedHill Biopharma Ltd., an Israeli company ("RedHill"). IntelGenx and RedHill each may be referred to herein individually as a "Party," or collectively as the "Parties".

RedHill Biopharma Ltd. – Co-Development and Commercialization Agreement (October 26th, 2012)

THIS CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this "Agreement") is made and entered into as of August 26, 2010 (the "Effective Date"), by and between IntelGenx Corp., a Canadian corporation ("IntelGenx"), and RedHill Biopharma Ltd., an Israeli company ("RedHill"). IntelGenx and RedHill each may be referred to herein individually as a "Party," or collectively as the "Parties".

Amendment No. 2 to the Co-Development and Commercialization Agreement (February 24th, 2011)

THIS AMENDMENT NO. 2 TO THE CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this Amendment) is made and entered into as of the 5th day of October 2010 (the Effective Date) by and between GLAXO GROUP LIMITED, a company organized under the laws of England and Wales with its principal place of business at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, United Kingdom (GSK) and HUMAN GENOME SCIENCES, INC., a Delaware corporation with its principal place of business at 14200 Shady Grove Road, Rockville, Maryland 20850 (HGS). GSK and HGS are sometimes referred to herein individually as a Party and collectively as the Parties.

IntelGenx Technologies Corp. – Co-Development and Commercialization Agreement (November 9th, 2010)

THIS CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this Agreement) is made and entered into as of August 26, 2010 (the Effective Date), by and between IntelGenx Corp., a Canadian corporation (IntelGenx), and RedHill Biopharma Ltd., an Israeli company (RedHill). IntelGenx and RedHill each may be referred to herein individually as a Party, or collectively as the Parties.

Exclusive License and Collaborative Research, Co-Development and Commercialization Agreement (November 5th, 2010)

This EXCLUSIVE LICENSE AND COLLABORATIVE RESEARCH, CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this Agreement) is made effective as of December 18, 2009, (the Effective Date), by and among ASTELLAS PHARMA INC., a Japanese corporation (API) and its indirect wholly owned subsidiary ASTELLAS US LLC, a Delaware limited liability company (AUS; collectively with API, Astellas), and AMBIT BIOSCIENCES CORPORATION, a Delaware corporation (Ambit).

Rules-Based Medicine Inc – Variation Agreement to Co-Development and Commercialization Agreement (March 16th, 2010)

THIS VARIATION AGREEMENT (Variation Agreement) is made and entered into as of the 19 day of December, 2009 by and among Rules-Based Medicine, Inc., a Delaware corporation (RBM); and Psynova Neurotech Limited, a company incorporated in England and Wales (Psynova).

Rules-Based Medicine Inc – CO-DEVELOPMENT and COMMERCIALIZATION AGREEMENT (December 23rd, 2009)

THIS AGREEMENT, effective as of the last date of execution by the parties hereto (hereinafter referred to as the Effective Date) is by and between Psynova Neurotech Ltd., having an address at St. Johns Innovation Centre, Cowley Road, Cambridge CB4 0WS, UK (hereinafter referred to as Psynova) and Rules Based Medicine, Inc. a corporation having its principal place of business at 3300 Duval Road, Austin, Texas 78759, USA (hereinafter referred to as RBM).

Co-Development and Commercialization Agreement Between Human Genome Sciences, Inc. And Glaxo Group Limited (February 26th, 2009)

THIS CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT is made effective as of the 1st day of August, 2006 (Effective Date) by and between Human Genome Sciences, Inc., a Delaware corporation having its principal place of business at 14200 Shady Grove Road, Rockville, Maryland 20850 (HGS) and Glaxo Group Limited, a company organized under the laws of England and Wales with its principal place of business at GlaxoWellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, United Kingdom (GSK). HGS and GSK shall be referred to herein collectively as Parties and individually as a Party.

Neose Technologies, Inc. – Amendment Number 1 to Research, Co-Development and Commercialization Agreement and Research License and Option Agreement (March 16th, 2007)

This Amendment Number 1 (the Amendment) to the Collaboration Agreement and the License Agreement (both as defined below) is effective as of October 20, 2006 (the Effective Date), and is by and between BioGeneriX AG, a corporation organized under the laws of the Federal Republic of Germany (BioGeneriX), and Neose Technologies, Inc., a corporation organized and existing under the laws of the state of Delaware (Neose).

Pdl Biopharma – Confidential Provisions Redacted Amended and Restated Co-Development and Commercialization Agreement (March 16th, 2006)

This Amended and Restated Co-Development and Commercialization Agreement (the Agreement) is entered into as of October 29, 2005 (the Amendment Effective Date), by and among PROTEIN DESIGN LABS, INC., a Delaware corporation having offices at 34801 Campus Drive, Fremont, California 94555 (PDL), and HOFFMANN-LA ROCHE INC., a New Jersey corporation having offices at 340 Kingsland Street, Nutley, New Jersey 07110 (Roche-Nutley) and F. HOFFMANN-LA ROCHE LTD of Basel, Switzerland (F. Roche) (Roche-Nutley and F. Roche are individually and collectively referred to as Roche).

Co-Development and Commercialization Agreement (March 15th, 2006)

This Co-Development and Commercialization Agreement (the Agreement) is entered into as of December 9, 2005, by and between Hoffmann-La Roche Inc., a corporation organized and existing under the laws of the State of New Jersey, with its principal place of business at 340 Kingsland Street, Nutley, New Jersey 07110 (Roche Nutley), and F. Hoffmann-La Roche Ltd, a Swiss Corporation, with its principal place of business at Grenzacherstrasse 124, CH-4070 Basel, Switzerland (Roche Basel), (Roche Nutley and Roche Basel are collectively referred to as Roche) and Maxygen Holdings Ltd., a company organized under the laws of Cayman Islands, British West Indies (Maxygen). Roche and Maxygen are each referred to herein individually as a Party, and collectively as the Parties.

Pdl Biopharma – Co-Development and Commercialization Agreement (November 5th, 2004)

This Co-Development and Commercialization Agreement is entered into as of September 14, 2004 (the Effective Date), by and among PROTEIN DESIGN LABS, INC., a Delaware corporation having offices at 34801 Campus Drive, Fremont, California 94555 (PDL), and HOFFMANN-LA ROCHE INC., a New Jersey corporation having offices at 340 Kingsland Street, Nutley, New Jersey 07110 (Roche-Nutley) and F. HOFFMANN-LA ROCHE LTD of Basel, Switzerland (F. Roche) (Roche-Nutley and F. Roche are hereinafter individually and collectively referred to as Roche).